Evotec stock slides near 52-week low after first-half loss
Published on 08/21/2026 at 18:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock (DE0005664809) is trading under pressure after the company reported first-half 2026 revenue of EUR300.1 million and adjusted EBITDA of negative EUR42.7 million, while the latest market commentary put the shares at EUR3.39 on August 21, 2026.
The same August 21, 2026 update said revenue fell 19.2 percent from the prior year period, and the adjusted EBITDA loss widened by EUR40.8 million year over year. Management also kept full-year 2026 guidance at EUR570 million to EUR610 million in revenue and negative EUR70 million to negative EUR105 million in adjusted EBITDA.
Guidance still points lower
The guidance range implies second-half 2026 revenue of EUR269.9 million to EUR309.9 million, which leaves limited room for a sharp rebound after the weak first half. The midpoint of the adjusted EBITDA outlook, negative EUR87.5 million, also signals that losses are expected to deepen versus the first six months.
Market data in the same commentary showed the stock at EUR3.39, only EUR0.20 above the 52-week low of EUR3.19 and 33 percent below the 200-day moving average of EUR5.06. A separate trading note from August 20, 2026 said the shares slipped intraday to EUR3.34, or 1.8 percent below the prior close at that time.
Analysts remain cautious
Consensus data on Evotec SE shows a HOLD view from 8 analysts, with an average target price of EUR4.586 and a low target of EUR3.50. That leaves the current share price below the average target and only slightly beneath the lowest published target in the consensus set.
The comparison is stark: the average target price is 35.1 percent above EUR3.39, while the stock is still 38 percent lower year to date and 45 percent lower over the past 12 months according to the market commentary. For investors, that gap between current trading and consensus target levels is now less important than whether the company can stabilize revenue and narrow losses in the second half.
Discovery platform pressure
Evotec's discovery and development platform depends on collaboration revenue, milestone timing, and project progression across its pharmaceutical partnerships. When those programs slow, the effect reaches both sales and profitability quickly, as the first-half 2026 numbers showed.
Shares and product context
The company's business spans small-molecule discovery, biologics, and translational research services for pharmaceutical and biotechnology partners. Just-Evotec Biologics is one of the better-known parts of that platform, and its performance feeds directly into the collaboration-driven revenue base.
Evotec shares last traded at EUR3.39 in the August 21, 2026 market commentary, with the stock still pinned near its 52-week low and well below its 200-day average.
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVT
Exchange: XETRA
Price (as of August 21, 2026): EUR3.39
Market cap: EUR595.0 million
Sector / Industry: Biotechnology / Biotechnology and Medical Research
Index membership: SDAX
